Expressing the sense of the House of Representatives that over 25 years of real-world evidence and hundreds of peer-reviewed studies proving that mifepristone is safe and effective should be respected, and law and policy governing access to lifesaving, time-sensitive medication abortion care in the United States should be equitable, transparent, and based on the best available peer-reviewed evidence-based science.

Sponsored By

Diana DeGette

Democrat · Colorado · House

1. Introduced in House

   May 14, 2026
2. Referred to Committee
3. Committee Markup

   May 14, 2026You Are Here

   The committee will review the bill, debate amendments, and vote on whether to advance it to the full chamber.

   What happens in markup?→
4. House Vote

   TBD

   The full chamber debates the bill, may amend it, and votes on whether to pass it.

5. Senate Consideration

   TBD

   If passed by the first chamber, the other chamber considers, may amend, and votes on the bill.

6. President's Signature

   TBD

   If passed by both chambers, the bill goes to the President to sign into law or veto.